VJHemOnc is committed to improving our service to you

MDS 2020 | Lenalidomide, mutations & MDS outcomes

VJHemOnc is committed to improving our service to you

Valeria Santini

Valeria Santini, MD, University of Florence, Florence, Italy, discusses the use of lenalidomide in the treatment of myelodysplastic syndromes (MDS) and the impact of different genetic aberrations on the efficacy of this drug. Dr Santini goes on to outline the use of immunosuppressive treatment in MDS. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter